<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="10/07/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10491412" creator="Noriko Katsu">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>10491412</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term sem="Organic_compound_other" id="T1" lex="renal_cell_carcinoma-derived_ganglioside">Renal cell carcinoma-derived <term sem="Organic_compound_other" id="A2" lex="gangliosides">gangliosides</term></term> suppress <term sem="Other" id="T2" lex="nuclear_factor-kappaB_activation"><term sem="Protein_complex" id="T3" lex="nuclear_factor-kappaB">nuclear factor-kappaB</term> activation</term> in <term sem="Cell_natural" id="T4" lex="T_cell">T cells</term>.</sentence>
<event id="E1">
<type class="Metabolism" />
<theme idref="A2" />
<clue><clueLoc>Renal cell carcinoma</clueLoc>-<clueType>derived</clueType> gangliosides suppress nuclear factor-kappaB activation in T cells.</clue>
</event>
<event id="E2">
<type class="Negative_regulation" />
<theme idref="E3" />
<cause idref="E1" />
<clue>Renal cell carcinoma-derived gangliosides <clueType>suppress</clueType> nuclear factor-kappaB activation in T cells.</clue>
</event>
<event id="E3">
<type class="Positive_regulation" />
<theme idref="T3" />
<clue>Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB <clueType>activation</clueType> <clueLoc>in T cells</clueLoc>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Activation of the <term sem="Protein_complex" id="T5" lex="transcription_factor_nuclear_factor-kappaB">transcription factor nuclear factor-kappaB</term> (<term sem="Protein_complex" id="T6" lex="NFkappaB">NFkappaB</term>) is impaired in <term sem="Cell_natural" id="T7" lex="T_cell">T cells</term> from <term sem="Multicellular_organism_natural" id="T8" lex="patient">patients</term> with <term sem="Tissue_natural" id="T9" lex="renal_cell_carcinoma">renal cell carcinomas</term> (<term sem="Tissue_natural" id="T10" lex="RCC">RCCs</term>).</sentence>
<event id="E4">
<type class="Positive_regulation" />
<theme idref="T6" />
<clue><clueType>Activation</clueType> <linkTheme>of</linkTheme> the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs).</clue>
</event>
<event id="E5">
<type class="Negative_regulation" />
<theme idref="E4" />
<clue>Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is <clueType>impaired</clueType> <clueLoc>in T cells</clueLoc> from patients with renal cell carcinomas (RCCs).</clue>
</event>
<sentence id="S3">In circulating <term sem="Cell_natural" id="T11" lex="T_cell">T cells</term> from a subset of <term sem="Multicellular_organism_natural" id="T12" lex="patient">patients</term> with <term sem="Tissue_natural" id="T13" lex="RCC">RCCs</term>, the suppression of <term sem="Other" id="T14" lex="NFkappaB_binding_activity"><term sem="Protein_complex" id="T15" lex="NFkappaB">NFkappaB</term> binding activity</term> is downstream from the <term sem="Other" id="T16" lex="stimulus-induced_degradation"><term sem="Other" id="A3">stimulus</term>-induced degradation</term> of the <term sem="Protein_family_or_group" id="T17" lex="cytoplasmic_factor">cytoplasmic factor</term> <term sem="Protein_molecule" id="T18" lex="IkappaBalpha">IkappaBalpha</term>.</sentence>
<event id="E6">
<type class="Cellular_physiological_process" />
<theme idref="T11" />
<clue>In <clueType>circulating</clueType> T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E7">
<type class="Negative_regulation" />
<theme idref="E8" />
<clue><clueLoc>In circulating T cells</clueLoc> from a subset of patients with RCCs, the <clueType>suppression</clueType> <linkTheme>of</linkTheme> NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E8">
<type class="Binding" />
<theme idref="T15" />
<clue>In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB <clueType>binding activity</clueType> is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E9">
<type class="Protein_catabolism" />
<theme idref="T18" />
<clue>In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced <clueType>degradation</clueType> <linkTheme>of</linkTheme> the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E30">
<type class="Positive_regulation" />
<theme idref="E9" />
<cause idref="A3" />
<clue>In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-<clueType>induced</clueType> degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E10">
<type class="Correlation" />
<theme idref="E7" />
<theme idref="E10" />
<clue>In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is <clueType>downstream</clueType> <linkTheme>from</linkTheme> the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<sentence id="S4"><term sem="Organic_compound_other" id="T19" lex="tumor-derived_soluble_product">Tumor-derived soluble products</term> from <term sem="Tissue_natural" id="T20" lex="cultured_RCC">cultured RCC</term> explants inhibit <term sem="Other" id="T21" lex="NFkappaB_activity"><term sem="Protein_complex" id="T22" lex="NFkappaB">NFkappaB</term> activity</term> in <term sem="Cell_natural" id="T23" lex="T_cell">T cells</term> from <term sem="Multicellular_organism_natural" id="T24" lex="healthy_volunteer">healthy volunteers</term>, despite a normal level of <term sem="Other" id="T25" lex="stimulus-induced_IkappaBalpha_degradation"><term sem="Other" id="A4">stimulus</term>-induced <term sem="Protein_molecule" id="T26" lex="IkappaBalpha">IkappaBalpha</term> degradation</term> in these cells.</sentence>
<event id="E11">
<type class="Negative_regulation" />
<theme idref="T22" />
<cause idref="T19" />
<clue>Tumor-derived soluble products from cultured RCC explants <clueType>inhibit</clueType> NFkappaB activity <clueLoc>in T cells from healthy volunteers</clueLoc>, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells.</clue>
<comment>NER: T19 sem mod, Protein_family_or_group -&gt; Other_oreganic_compound</comment>
</event>
<event id="E12">
<type class="Protein_catabolism" />
<theme idref="T26" />
<clue>Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha <clueType>degradation</clueType> <clueLoc>in these cells</clueLoc>.</clue>
</event>
<event id="E31">
<type class="Positive_regulation" />
<theme idref="E12" />
<cause idref="A4" />
<clue>Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-<clueType>induced</clueType> IkappaBalpha degradation in these cells.</clue>
</event>
<event assertion="non-exist" id="E13">
<type class="Negative_regulation" />
<theme idref="E12" />
<clue>Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a <clueType>normal level</clueType> <linkTheme>of</linkTheme> stimulus-induced IkappaBalpha degradation in these cells.</clue>
</event>
<sentence id="S5">The inhibitory agent has several features characteristic of a <term sem="Organic_compound_other" id="T27" lex="ganglioside">ganglioside</term>, including sensitivity to <term sem="Protein_molecule" id="T28" lex="neuraminidase">neuraminidase</term> but not <term sem="Other" id="T29" lex="protease_treatment"><term sem="Protein_family_or_group" id="T30" lex="protease">protease</term> treatment</term>; <term sem="Other" id="T31" lex="hydrophobicity">hydrophobicity</term>; and molecular weight less than 3 kDa.</sentence>
<event id="E32">
<type class="Metabolism" />
<theme idref="T19" />
<clue><corefTheme>The inhibitory agent</corefTheme> has several features characteristic of a ganglioside, including <clueType>sensitivity</clueType> to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa.</clue>
</event>
<event id="E14">
<type class="Positive_regulation" />
<theme idref="E32" />
<theme idref="T28" />
<clue>The inhibitory agent has several features characteristic of a ganglioside, including sensitivity <linkCause>to</linkCause> neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa.</clue>
</event>
<event id="E33">
<type class="Protein_metabolism" />
<theme idref="T19" />
<clue><corefTheme>The inhibitory agent</corefTheme> has several features characteristic of a ganglioside, including <clueType>sensitivity</clueType> to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa.</clue>
</event>
<event assertion="non-exist" id="E15">
<type class="Positive_regulation" />
<theme idref="E33" />
<theme idref="T28" />
<clue>The inhibitory agent has several features characteristic of a ganglioside, including sensitivity <linkCause>to</linkCause> neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa.</clue>
</event>
<sentence id="S6">Indeed, we detected <term sem="Organic_compound_other" id="T32" lex="ganglioside">gangliosides</term> in supernatants from <term sem="Cell_natural" id="T33" lex="RCC_explant">RCC explants</term> and not from adjacent <term sem="Tissue_natural" id="T34" lex="normal_kidney_tissue">normal kidney tissue</term>.</sentence>
<sentence id="S7"><term sem="Organic_compound_other" id="T35" lex="ganglioside">Gangliosides</term> prepared from <term sem="Cell_component" id="T36" lex="RCC_supernatant">RCC supernatants</term>, as well as the <term sem="Organic_compound_other" id="T37" lex="purified_bovine_ganglioside">purified bovine <term sem="Organic_compound_other" id="T38" lex="ganglioside">gangliosides</term></term> <term sem="Organic_compound_other" id="A6" lex="G(m1)">G(m1)</term> and <term sem="Organic_compound_other" id="A7" lex="G(d1a)">G(d1a)</term>, suppressed <term sem="Protein_complex" id="T39" lex="NFkappaB">NFkappaB</term> binding activity in <term sem="Cell_natural" id="T40" lex="T_cell">T cells</term> and reduced expression of the <term sem="Protein_family_or_group" id="T41" lex="cytokine">cytokines</term> <term sem="Protein_molecule" id="T42" lex="IL-2">IL-2</term> and <term sem="Protein_molecule" id="T43" lex="IFN-gamma">IFN-gamma</term>.</sentence>
<event id="E16">
<type class="Binding" />
<theme idref="T39" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB <clueType>binding activity</clueType> <clueLoc>in T cells</clueLoc> and reduced expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E17">
<type class="Negative_regulation" />
<theme idref="E16" />
<cause idref="T35" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), <clueType>suppressed</clueType> NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E18">
<type class="Negative_regulation" />
<theme idref="E16" />
<cause idref="A6" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), <clueType>suppressed</clueType> NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E19">
<type class="Negative_regulation" />
<theme idref="E16" />
<cause idref="A7" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), <clueType>suppressed</clueType> NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E20">
<type class="Negative_regulation" />
<theme idref="E26" />
<cause idref="T35" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E21">
<type class="Negative_regulation" />
<theme idref="E26" />
<cause idref="A6" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E22">
<type class="Negative_regulation" />
<theme idref="E26" />
<cause idref="A7" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E23">
<type class="Negative_regulation" />
<theme idref="E27" />
<cause idref="T35" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E24">
<type class="Negative_regulation" />
<theme idref="E27" />
<cause idref="A6" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E25">
<type class="Negative_regulation" />
<theme idref="E27" />
<cause idref="A7" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E26">
<type class="Gene_expression" />
<theme idref="T42" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced <clueType>expression</clueType> <linkTheme>of</linkTheme> the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E27">
<type class="Gene_expression" />
<theme idref="T43" />
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced <clueType>expression</clueType> <linkTheme>of</linkTheme> the cytokines IL-2 and IFN-gamma.</clue>
</event>
<sentence id="S8">Taken together, our findings suggest that <term sem="Organic_compound_other" id="T44" lex="tumor-derived_ganglioside">tumor-derived <term sem="Organic_compound_other" id="T45" lex="ganglioside">gangliosides</term></term> may blunt <term sem="Other" id="T46" lex="antitumor_immune_response">antitumor immune responses</term> in <term sem="Multicellular_organism_natural" id="T47" lex="patient">patients</term> with <term sem="Tissue_natural" id="T48" lex="RCC">RCCs</term>.</sentence>
<event id="E28">
<type class="Metabolism" />
<theme idref="T45" />
<clue>Taken together, our findings suggest that <clueLoc>tumor</clueLoc>-<clueType>derived</clueType> gangliosides may blunt antitumor immune responses in patients with RCCs.</clue>
</event>
<event uncertainty="probable" id="E29">
<type class="Negative_regulation" />
<theme idref="T46" />
<cause idref="E28" />
<clue>Taken together, our findings suggest that tumor-derived gangliosides may <clueType>blunt</clueType> antitumor immune responses in patients with RCCs.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
